ALNYLAM PHARMACEUTICALS, INC. - 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed on October 3, 2019, reporting an event that occurred on September 27, 2019. The registrant is Alnylam Pharmaceuticals, Inc., a Delaware corporation with principal executive offices in Cambridge, Massachusetts.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or margin data. The specific financial event reported is the repayment of debt:
- Debt Repaid: $30 million outstanding principal amount.
- Lender: Wells Fargo Bank, National Association.
- Borrower: Alnylam U.S., Inc. (subsidiary).
- Guarantor: Alnylam Pharmaceuticals, Inc.
- Original Maturity Date: April 29, 2021.
Material Changes
On September 27, 2019, the company repaid the full outstanding principal of its credit agreement. Consequently, the Credit Agreement terminated in accordance with its terms. This action reduces the company's outstanding debt obligations.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of risks and contingencies beyond the termination of the specific credit agreement.
Investor Verification Checklist
- Confirm the $30 million debt repayment was funded from existing cash reserves or new financing.
- Review the company's most recent 10-Q or 10-K to assess the impact of this repayment on total liquidity and debt-to-equity ratios.
- Verify if there are other outstanding credit facilities or debt instruments not mentioned in this specific 8-K.